Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug-eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries. It will specifically target blockages that resulted in claudication (leg pain upon walking).

DAIC is seeking readers’ nominations for state-of-the-art cardiac departments and heart centers based on their use of cutting-edge technology. Key factors to be considered include how new technologies are being used to help improve patient outcomes, increase efficiency, reduce costs, increase patient volume, or increase reimbursements/revenues.

December 20, 2011 – After a heart attack, the portions of the heart damaged by a lack of oxygen become scar tissue. Researchers have long sought ways to avoid this scarring, which can harden the walls of the heart, lessen its ability to pump blood throughout the body and eventually lead to heart failure. But new research from the University of North Carolina at Chapel Hill School of Medicine shows that interrupting this process can weaken heart function even further.

December 20, 2011 – Boston Scientific reported positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the Ion (Taxus Element) paclitaxel-eluting patinum chromium stent system versus prior-generation paclitaxel-eluting stents.  Results were presented today by PERSEUS clinical program principal investigators Louis Cannon, M.D., of the Cardiac and Vascular Research Center of Northern Michigan in Petoskey, Mich., and Dean Kereiakes, M.D., medical director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

December 20, 2011 — Aware Inc. announced the introduction of two new server-based software products: AccuRad REM Server and WebView Module for AccuRad ImageShare Server. The products leverage advanced features of the company's AccuRad Server infrastructure to address two different applications: radiation exposure monitoring and viewing of radiology and pathology images.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now